Valneva Shares: Analysts See Substantial Upside Potential

Despite recent market jitters affecting investor sentiment, the underlying financial performance of French vaccine specialist Valneva tells a different story. While the company’s share price has experienced a significant downturn, its recently released nine-month results for 2025 were robust, with management reaffirming its full-year outlook even amidst a challenging operating climate. Adding a jolt of optimism to this gloomy market atmosphere, a prominent analyst firm has issued a striking assessment, suggesting the stock’s potential could far exceed its current trading level.

The perspective from investment bank Stifel provides a compelling counter-narrative to the current share price weakness. The firm has reiterated its “Buy” recommendation, attaching a price target of Read more...